Fig. 1: Identification of PLOD3 as a novel regulator responsible for Trastuzumab resistance in gastric cancer.
From: PLOD3 contributes to HER-2 therapy resistance in gastric cancer through FoxO3/Survivin pathway
A Analysis of genes responsible for Trastuzumab resistance in gastric cancer from TCGA database and RNA-Seq database(GSE26899). B The trastuzumab-resistant GC cell lines were generated by treating HER-2 positive parent cell lines N87 and SNU-216 with trastuzumab, and the resistance potentials were verified by MTT assays. C The siRNA depletion of indicated targets were conducted in NCI-N87 and SNU-216 cells followed by MTT assays to determine the inhibition efficiency. Silencing PLOD3 significantly decreased cell proliferation when compared to other genes when treated with Trastuzumab. D Expression of PLOD3 in Tr cells and parental cells were determined by quantitative PCR and western blot. E Established Tr cell lines with PLOD3 depletion by two independent shRNAs (sh1, sh2) and validated by western blot. F The proliferation in both N87 and SUN-216 Tr cells were confirmed by MTT.
